Co-Authors
This is a "connection" page, showing publications co-authored by HASHEM EL-SERAG and GEORGE CHOLANKERIL.
Connection Strength
2.403
-
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
Score: 0.770
-
Diverging Three-Year Survival Outcomes Among Contemporary ALD and MASH Liver Transplant Recipients. Am J Gastroenterol. 2026 Jun 09.
Score: 0.248
-
Development of retrieval-augmented generation-based large language model for drug-induced liver injury using Livertox data. Hepatol Commun. 2026 Mar 01; 10(3).
Score: 0.243
-
Improved liver transplant outcomes for patients with hilar cholangiocarcinoma following implementation of the MMAT-3 policy. Liver Transpl. 2026 Jun 01; 32(6):823-829.
Score: 0.238
-
Temporal Changes in Risk Factors of Hepatocellular Carcinoma in a Prospective Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2025 Jun; 23(7):1268-1270.e2.
Score: 0.224
-
Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. J Can Assoc Gastroenterol. 2024 Oct; 7(5):331-345.
Score: 0.219
-
Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
Score: 0.194
-
Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system. Hepatol Commun. 2026 Jan 01; 10(1).
Score: 0.060
-
Racial and ethnic disparities in extended criteria allograft use for liver transplantation. Liver Transpl. 2025 Jun 01; 31(6):844-847.
Score: 0.056
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
Score: 0.056
-
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
Score: 0.047
-
Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
Score: 0.047